NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Sotorasib for previously treated KRAS G12c mutated metastatic non-small-cell lung cancer ID3780

Final stakeholder list

Consultees	Commentators (no right to submit or appeal)
Company • Amgen (sotorasib, proposed international non-proprietary name) Patient/carer groups • Black Health Agency • British Lung Foundation • Cancer Black Care • Cancer Equality • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Roy Castle Lung Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • UK Lung Cancer Coalition Professional groups • Association of Cancer Physicians • Association of Respiratory Nurse Specialists • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Thoracic Oncology Group • British Thoracic Society • Cancer Research UK • Lung Cancer Nursing UK • National Heart and Lung Institute • Primary Care Respiratory Society UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians	General • All Wales Therapeutic and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Possible comparator companies • Accord Healthcare (cisplatin, carboplatin, docetaxel, gemcitabine, vinorelbine) • AstraZeneca (osimertinib) • Boehringer Ingelheim (nintedanib) • Bristol-Myers Squibb (nivolumab) • Consilient Health (carboplatin, gemcitabine, vinorelbine) • Eli Lilly (pemetrexed) • Hospira (cisplatin, carboplatin, docetaxel, gemcitabine) • Medac (vinorelbine) • Merck Sharp & Dohme (bevacizumab, pembrolizumab) • Novartis (ceritinib)

© National Institute for Health and Care Excellence 2021. All rights reserved.

Consultees	Commentators (no right to submit or appeal)
• Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society <u>Others</u> • Department of Health and Social care • NHS England • NHS North East Hampshire and Farnham CCG • NHS South Gloucestershire CCG • Welsh Government	• Pfizer (bevacizumab, lorlatinib) • Pierre Fabre (vinorelbine) • Roche (atezolizumab, bevacizumab) • Sandoz (cisplatin) • Seacross (docetaxel, pemetrexed) • Sun (gemcitabine) • Takeda (brigatinib) <u>Relevant research groups</u> • Cochrane Lung Cancer Group • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research <u>Associated Public Health Groups</u> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

<u>Consultees</u>

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

<u>Commentators</u>

[1]Non-company consultees are invited to submit statements relevant to the group they are representing.

© National Institute for Health and Care Excellence 2021. All rights reserved.

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

© National Institute for Health and Care Excellence 2021. All rights reserved.